Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.
To Browse a Full Report with Toc: http://www.researchmoz.us/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Erbitux for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Erbitux performance
- Obtain sales forecast for Erbitux from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile Erbitux 34
Table 8: Erbitux SWOT Analysis, 2014 36
Table 9: Global Sales Forecast ($m) for Erbitux, 2013-2023 37
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 52
To Browse a Full Report with Toc: http://www.researchmoz.us/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.
To Browse a Full Report with Toc: http://www.researchmoz.us/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Erbitux for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Erbitux performance
- Obtain sales forecast for Erbitux from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile Erbitux 34
Table 8: Erbitux SWOT Analysis, 2014 36
Table 9: Global Sales Forecast ($m) for Erbitux, 2013-2023 37
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 52
To Browse a Full Report with Toc: http://www.researchmoz.us/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
No comments:
Post a Comment